Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Euroz Hartleys Healthcare Forum 2023
20 slides from Proteomics International Laboratories's conference presentation, Feb 2, 2023
Slide 1: Proteomics International Investor Presentation
ASX: PIQ Proteomics International LABORATORIES LTD Investor Presentation Euroz Hartleys Healthcare Forum 2 February 2023 Dr. Richard Lipscombe Managing Director 1
Slide 2: Disclaimer
Disclaimer ASX: PIQ This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in
Slide 3: Corporate Snapshot – 30/01/2023
Proteomics International Laboratories Ltd ASX: PIQ Corporate Snapshot – 30/01/2023 A medical technology company at the forefront of ASX code PIQ precision medicine and predictive diagnostics Share Price A$1.125 Diagnostics (Dx) Shares on issue (+5.7m options) 118m PromarkerD Market Capitalisation A$
Slide 4: Promarker – Platform Technology
Promarker – Platform Technology ASX: PIQ PromarkerTM is a platform technology that can identify unique protein biomarkers ‘fingerprints’ The platform identifies and links the unique protein biomarkers to specific diseases, enabling Proteomics International to create novel diagnostic tests 4
Slide 5: PromarkerD
Promarker D PROACTIVELY CHANGING RENAL HEALTHCARE Asimple blood test for predicting diabetic kidney disease
Slide 6: Problem and Solution
Problem and Solution ASX: PIQ Current standard-of-care diagnostics • Existing tests (known as eGFR and ACR) can only detect chronic kidney disease once it is already present • Current standard-of-care tests cannot predict the onset Roadblock of diabetic kidney disease The Problem • If unchecked, pat
Slide 7: PromarkerD is Revenue Ready
PromarkerD is Revenue Ready ASX: PIQ Key highlights towards a global roll-out Enormous Market ✓ 537m adults have diabetes globally: 1-in-3 currently have diabetic kidney disease (DKD) Peer reviewed publications – Clinical & analytical validity proven (Sensitivity 86%); High Statistical Performance ✓
Slide 8: PromarkerD – Simple Integration & Utilisation
PromarkerD – Simple Integration & Utilisation ASX: PIQ Blood sample drawn Biomarkers analysed Results analysed by Results and intervention plan PromarkerD Hub software delivered Sample is drawn at clinic or Laboratory uses a standard Cloud based algorithm, the Clinician delivers results to patient p
Slide 9: PromarkerD Market Opportunity
PromarkerD Market Opportunity ASX: PIQ Diabetes incidence and Patent portfolio 45% undiagnosed Country Patent/Application No Patent Status No. Diabetics1 Australia 2011305050 Granted 1,491,800 Brazil BR112013006740 Granted 15,733,600 Canada 2811654 Granted 2,974,000 China ZL201180053583.9 Granted 14
Slide 10: PromarkerD – Route to US and Global Markets
PromarkerD – Route to US and Global Markets ASX: PIQ Diagnostic laboratory Key Markets licenses PromarkerDTM United States • Binding Letter of Intent signed with Sonic Healthcare USA • LOI details terms and conditions to market and sell PromarkerD in the USA Immunoassay kits manufactured and • Proma
Slide 11: Diagnostics Pipeline
Diagnostics Pipeline ASX: PIQ The Promarker™️ Research Further Global Potential in New Markets Pipeline & Timeline • Employs the Promarker™️ technology platform to develop novel intellectual property • Targeting new diagnostic tests in areas of significant unmet need • Enormous markets and revenue p
Slide 12: In Development: Endometriosis, Oesophageal Cancer
In Development: Endometriosis • Endometriosis is a common and painful disease where tissue that normally lines the uterus grows into other organs • Currently diagnosis takes an average of 7.5 years and requires invasive surgery (laparoscopy) • Affects 1 in 9 women and costs Australia over AU$10 bill
Slide 13: Timeline & Milestones
Timeline & Milestones ASX: PIQ 2022 Achievements 2023 Targets & Milestones 29 Aug 2022 14 Dec 2022 1 Aug 2022 OxiDx P/L spin- UK NICE Potential breakthrough out launched for publishes Finalisation of 16 Jun 2022 blood test able to detect oxidative stress Medtech Sonic Healthcare Completion of 7 Feb
Slide 14: Value Inflection Points
Value Inflection Points ASX: PIQ Share Price Catalysts throughout CY23 Exceptional Global Opportunity 1H 2H Milestone CY23 CY23 Impact ➢ Disruptive, cutting-edge technology & proven in-house diagnostics platform PromarkerD Execution of Sonic Healthcare USA licence; ➢ PromarkerD test de-risked, paten
Slide 15: Peer Comparison
Peer Comparison ASX: PIQ Market Share FY22 FY22 Net Stock Code Company Focus Capitalisation Price Revenue Profit/Loss Proteomics Predictive blood test measuring novel protein biomarkers for DKD; simple, cost effective, commercial ready. International PIQ.ASX Pipeline of novel diagnostic tests in dev
Slide 16: Contact
Contact ASX: PIQ Dr Richard Lipscombe Kyle Moss Managing Director Corporate Advisor T: +61 8 9389 1992 Euroz Hartleys E: enquiries@proteomicsinternational.com T: +61 9488 1400 www.proteomicsinternational.com E: kmoss@eurozhartleys.com Dirk van Dissel Investor Relations & Corporate Advisor Candour Ad
Slide 17: Supplemental
Supplemental ASX: PIQ 17
Slide 18: Board of Directors
Board of Directors ASX: PIQ Neville Gardiner BBus (Accounting and Business Law) (Curtin), Non-Executive Chair Seasoned finance professional with over 30 years’ experience providing corporate advice to Boards of public and private companies. South & He was Co-Founder and MD of Torridon Partners, an i
Slide 19: PromarkerD – Results & Intervention
PromarkerD – Results & Intervention ASX: PIQ How PromarkerD results are delivered LOW RISK MODERATE RISK HIGH RISK RISK SCORE % 0 10 20 100 Prognostic 16% indicates a moderate risk of decline in kidney function* Risk Score Intervention Testing Regimen Low Risk • Standard diabetes management Test Ann
Slide 20: PromarkerD in the Clinic
PromarkerD in the Clinic ASX: PIQ PromarkerD significantly enhances diabetic kidney disease diagnosis and management Peer reviewed PromarkerD tested on over 5,000 patients in 4-year clinical studies PromarkerD predicted 86% of otherwise healthy patients with T2D who went on to develop chronic kidney
Proteomics International Laboratories — Euroz Hartleys Healthcare Forum 2023 on 6ix